Combivent

WikiDoc Resources for Combivent
Articles
Most recent articles on Combivent Most cited articles on Combivent Review articles on Combivent Articles on Combivent in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Combivent Images of Combivent Photos of Combivent Podcasts & MP3s on Combivent Videos on Combivent
Evidence Based Medicine
Cochrane Collaboration on Combivent Bandolier on Combivent TRIP on Combivent
Clinical Trials
Ongoing Trials on Combivent at Clinical Trials.gov Trial results on Combivent Clinical Trials on Combivent at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Combivent NICE Guidance on Combivent NHS PRODIGY Guidance FDA on Combivent CDC on Combivent
Books
Books on Combivent
News
Combivent in the news Be alerted to news on Combivent News trends on Combivent
Commentary
Blogs on Combivent
Definitions
Definitions of Combivent
Patient Resources / Community
Patient resources on Combivent Discussion groups on Combivent Patient Handouts on Combivent Directions to Hospitals Treating Combivent Risk calculators and risk factors for Combivent
Healthcare Provider Resources
Symptoms of Combivent Causes & Risk Factors for Combivent Diagnostic studies for Combivent Treatment of Combivent
Continuing Medical Education (CME)
CME Programs on Combivent
International
Combivent en Espanol Combivent en Francais
Business
Combivent in the Marketplace Patents on Combivent
Experimental / Informatics
List of terms related to Combivent

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Synonyms / Brand Names: Ipratropium Bromide + Salbutamol Sulfate, Ipratropium/Salbutamol, Combivent Inhalation Aerosol, Combivent Inhalation Solution

Dosing and Administration

The dose of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours. Safety and efficacy of additional doses of Combivent Inhalation Aerosol beyond 12 puffs/24 hours have not been studied. Also, safety and efficacy of extra doses of ipratropium or albuterol in addition to the recommended doses of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol have not been studied. It is recommended to “test-spray” three times before using for the first time and in cases where the aerosol has not been used for more than 24 hours. Avoid spraying into eyes.

---

Adapted from the FDA Package Insert. Template:SIB Template:WH